Phase III Study of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome

Conditions:   Glomerulonephritis, Membranous;   Nephrotic Syndrome，Idiopathic Interventions:   Drug: Rituximab (genetical recombination);   Drug: Placebo Sponsor:   Shoichi Maruyama MD PhD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials